Question 10 of 20 Fundamentals Interpretation
How do US and EU orphan designations differ?
Short answer
The US defines a rare disease as affecting fewer than 200,000 people in the United States, and orphan approval brings 7 years of market exclusivity. The EU threshold is no more than 5 in 10,000 people, the condition must be life threatening or chronically debilitating, and exclusivity is 10 years per designated indication.
Why
The thresholds measure different things. The US counts people, the EU counts prevalence. Both also allow designation where the medicine is not expected to recover its development costs.
The EU adds two criteria the US does not have in the same form: the condition must be life threatening or chronically debilitating, and if a satisfactory treatment exists the new medicine must offer significant benefit. EMA's Committee for Orphan Medicinal Products gives an opinion within 90 days of validation, and the European Commission grants the designation. In the US, FDA grants designation, and under 21 CFR 316.31 it will not approve the same drug for the same use for another sponsor for 7 years after approval.
EU market exclusivity is 10 years, can grow by 2 years with a compliant paediatric investigation plan, and can be cut to 6 years if the medicine no longer meets the criteria. A designation is not an approval. A sponsor can hold designations in both regions and still fail to get either approval.
The December 2025 political agreement on EU pharmaceutical reform may change the EU incentives once it applies.
A strong answer covers
- US fewer than 200,000 people versus EU 5 in 10,000
- EU seriousness and significant benefit criteria
- 7 versus 10 years of exclusivity
- EU paediatric extension and possible reduction to 6 years
- Designation is not approval
Common mistakes
- Applying the US threshold to the EU or the other way round.
- Thinking orphan designation shortens the evidence needed for approval.
- Assuming exclusivity covers all uses of the molecule rather than the designated indication.
The interviewer might ask next
How would a sponsor show significant benefit in the EU when an approved treatment already exists?